Add Yahoo as a preferred source to see more of our stories on Google. A genetic eye disorder Ocugen has dosed the first subject in its Phase II/III GARDian3 trial of modifier gene therapy candidate, ...
Enrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, reflecting strong interest from investigators and ...
Ocugen Inc. (NASDAQ:OCGN) is one of the popular penny stocks on Robinhood to buy. On March 2, Ocugen, Inc. (NASDAQ:OCGN) announced the completion of patient enrollment for its Phase 3 liMeliGhT ...
Please provide your email address to receive an email when new articles are posted on . Low-dose OCU410 slowed lesion growth, preserved retinal tissue and stabilized visual function in three patients.
Ocugen, Inc., a biotechnology company focused on gene therapies for blindness diseases, announced its participation in two significant upcoming conferences: the ARVO 2025 Annual Meeting in Salt Lake ...
MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the ...
MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (OCGN) (Ocugen or the Company), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results